NSAIDs and COX-2-Selective Inhibitors

SPEC - Essentials of Pain Medicine and Regional Anesthesia (Reprint)

Volumn , Issue , 2005, Pages 141-158

  Katz, Jeffrey A ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882516408     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06651-1.50020-4     Document Type: Chapter

References (203)

1. Clive D, Stoff J Renal syndromes associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1984, 310:563-572.
2. United States, 1991. Stat Bull Metropol Insur Co 1992, 73:25-34. Anti-arthritic medication usage.
3. Garner A Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol 1992, 27(Suppl 193):83-89.
4. Larkai E, Smith J, Lidsky M, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987, 82:1153-1158.
5. Singh G Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Therapeutics 2000, 7:115-121.
6. Plotz P Aspirin and salicylate. Textbook of Rheumatology 1981, 740-767. W.B. Saunders, Philadelphia. W. Kelly, E. Harris, S. Ruddy, C. Sledge (Eds.).
7. Wallace J Nonsteroidal anti-inflammatory drugs and gastro-enteropathy: The second hundred years. Gastroenterology 1997, 112:1000-1016.
8. Vane J Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971, 231:232-235.
9. Flower R, Moncada S, Vane J Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. The Pharmacological Basis of Therapeutics 1985, Macmillan, New York. ed 7. A. Gilman, L. Goodman, T. Rall (Eds.).
10. Björkman R Central antinociceptive effects of nonsteroidal and antiinflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthes Scand 1995, 39(Suppl):9-44.
11. Parr G, Darekar B, Fletcher A, et al. Joint pain and quality of life: Results of a randomized trial. Br J Clin Pharmacol 1989, 27:235-242.
12. Eisenberg E, Berkey C, Carr D, et al. Efficacy and safety of non-steroidal antiinflammatory drugs for cancer pain: A meta-analysis. J Clin Oncology 1994, 12:2756-2765.
13. Physicians' Desk Reference, ed 58 2004, Thompson PDR, Montvale, NJ.
14. McCormack K, Brune K Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. Drugs 1991, 41:533-547.
15. Svensson C, Yaksh T The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002, 42:553-583.
16. Ferreira S Prostaglandins, aspirin-like drugs and analgesia. Nature 1972, 240:200-203.
17. Levine JD, Lau W, Kwiat G, Goetzl EJ Leukotriene B4 produces hyperalgesia that is dependent upon polymorphonuclear leukocytes. Science 1984, 225:743.
18. McCormack K The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 1994, 47(Suppl):28-45.
19. Byers MR, Bonica JJ Peripheral pain mechanisms and nociceptor plasticity. Bonica's Management of Pain 2001, 27-72. Lippincott Williams & Wilkins, Philadelphia, PA. ed 3. J.D. Loeser, S.H. Butler, C.R. Chapman, D.C. Turk (Eds.).
20. Vasko M Prostaglandin-induced neuropeptide release from spinal cord. Prog Brain Res (Neth) 1995, 104:367-380.
21. England S, Bevan S, Docherty R PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J Physiol 1996, 495:429-440.
22. Ahmadi S, Lippross S, Neuhuber W, Zeilhofer H PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nature Neurosci 2002, 5:34-40.
23. Vasko M Prostaglandin-induced neuropeptide release from spinal cord. Prog Brain Res 1995, 104:367-380.
24. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001, 410:471-475.
25. Brune K Spinal cord effects of antipyretic analgesics. Drugs 1994, 47(Suppl 5):21-27.
26. DeWitt D, Meade E, Smith W PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993, 95(Suppl 2A):40-43.
27. Simmons D, Xie W, Chipman J, et al. Multiple cyclooxygenases: Cloning a mitogen-inducible form. Prostaglandins, Leukotrienes, Lipoxins, and PAF 1991, 67-78. Plenum Press, New York. J.M. Bailey (Ed.).
28. Kujubu D, Reddy S, Fletcher B, Herschman H Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem 1993, 268:5425-5430.
29. Crofford L COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol 1997, 24(S9):15-19.
30. Zhu X, Conklin D, Eisenach JC Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain. Pain 2003, 104:15-23.
31. Botting R Mechanism of action of acetaminophen: Is there a cyclooxygenase 3?. Clin Infect Diseases 2000, 31:S202-S210.
32. Simmons D Variants of cyclooxygenase-1 and their roles in medicine. Thrombosis Res 2003, 110:265-268.
33. Bela K, Snipes J, Isse T, et al. Putative cyclooxygenase-3 expression in rat brain cells. J Cerebral Blood Flow Metab 2003, 23:1287-1292.
34. Ziel R, Krupp P The significance of inhibition of prostaglandin synthesis in the selection of non-steroidal anti-inflammatory agents. Int J Clin Pharmacol Biopharm 1975, 12:186-191.
35. Abramson S Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1991, 3:336-340.
36. Ferreira S Prostaglandins: Peripheral and central analgesia. Advances in Pain Research and Therapy 1983, 5. Raven Press, New York. J.J. Bonica, U. Lindblom, A. Iggo (Eds.).
37. Willer J, De Broucker T, Bussel B Central analgesic effects of ketoprofen in humans: Electrophysiological evidence for a supraspinal mechanism in a double-blind and cross-over study. Pain 1989, 38:1-7.
38. Carlsson K, Monzel W, Jurna I Depression by morphine and the non-opioid analgesic agents metamizol, lysine acetylate and paracetamol, of activity in rat thalamus neurons evoked by electrical stimulation of nociceptive afferents. Pain 1988, 32:313-326.
39. Taiwo Y, Levine J Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 1988, 8:1346-1349.
40. Fabbri A, Cruccu G, Sperti P, et al. Piroxicam-induced analgesia: Evidence for a central component which is not opioid mediated. Experientia 1992, 48:1139-1142.
41. McCormack K, Brune K Dissociation between the anti-nociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs: A survey of their analgesic efficacy. Drugs 1991, 41:533-547.
42. Malmberg A, Yaksh T Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclo-oxygenase inhibition. Science 1992, 257:1276-1279.
43. Catania A, Arnold J, Macaluso A, et al. Inhibition of acute inflammation in the periphery by central action of salicylates. Proc Natl Acad Sci USA 1991, 88:8544-8547.
44. Taiwo Y, Levine J Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 1988, 8:1346-1349.
45. Carlsson K, Jurna I Central analgesic effect of paracetamol manifested by depression of nociceptive activity in thalamic neurons of the rat. Neurosci Lett 1987, 77:339-343.
46. Shyu K, Lin M Hypothalamic monoaminergic mechanisms of aspirin-induced analgesia in monkeys. J Neural Transm 1985, 62:285-293.
47. Carlsson K, Helmreich J, Jurna I Activation of inhibition from the periaqueductal grey matter mediates central analgesic effect of metamizol (Dipyrone). Pain 1986, 27:373-390.
48. Vescovi P, Passeri M, Gerra G, Grossi E Naloxone inhibits the early phase of diclofenac analgesia in man. Pain Clinic 1987, 19:151-155.
49. Bannwarth B, Netter P, Pourel J, et al. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomed Pharmacother 1989, 43:121-126.
50. Netter P, Lapicque F, Banwarth B, et al. Diffusion in intramuscular administered ketoprofen into the cerebrospinal fluid. Eur J Pharmacol 1985, 29:319-321.
51. Tegeder I, Niederberger E, Vetter G, et al. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E2 release in the spinal cord. J Neurochem 2001, 79:777-786.
52. Aronoff D, Neilson E Antipyretics: Mechanisms of action and clinical use in fever suppression. Am J Med 2001, 111:304-315.
53. Day R, Graham G, Williams K, Brooks P Variability in response to NSAIDs - Fact or fiction?. Drugs 1988, 36:643-651.
54. Day R, Graham G, Williams K, et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1987, 33:384-433.
55. Dukes M, Lunde I The regulatory control of non-steroidal anti-inflammatory drug preparations within individual rheumatology private practices. J Rheumatol 1989, 16:1253-1258.
56. Kurumbail R, Stevens A, Gierse J, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature V 1996, 384:644-648.
57. Fosslien E Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000, 37:431-502.
58. Carabaza A, Cabré F, Rotllan E, et al. Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J Clin Pharmacol 1996, 36:505-512.
59. Geisslinger G, Schaible H New insights into the site and mode of antinociception action of flurbiprofen enantiomers. J Clin Pharmacol 1996, 36:513-520.
60. Mauleon D, Artigas R, Garcia M, Carganico G Preclinical and clinical development of dexketoprofen. Drugs 1996, 52(Suppl 5):24-45.
61. Verbeeck R, Blackburn J, Lowewen G Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1983, 8:297-331.
62. Denson D, Katz J Nonsteroidal antiinflammatory agents. Practical Management of Pain 1992, 606-619. Mosby Year Book, St Louis. ed 2. P. Raj (Ed.).
63. Adams S Non-steroidal, anti-inflammatory drugs, plasma half-lives, and adverse reactions. Lancet 1987, 2:1204-1205.
64. Murray M, Brater D Non-steroidal anti-inflammatory drugs. Clinics Geriat Med 1990, 6:365-397.
65. Levy G, Tsuchiya T Salicylate accumulation kinetics in man. N Engl J Med 1972, 287:430-432.
66. Hayes A Therapeutic implications of drug interactions with acetaminophen and aspirin. Arch Intern Med 1981, 141:301-304.
67. Brune K Clinical relevance of nonsteroidal anti-inflammatory drug pharmacokinetics. Eur J Rheumatol Inflamm 1987, 8:18-23.
68. Bloom B Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med Suppl 1988, 2A:20-24.
69. Gabriel S, Fehring R Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986-1990. J Clin Epidemiol 1992, 45:1041-1044.
70. Katz J, Daltroy L, Brennan T, et al. Informed consent and the prescription of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1992, 35:1257-1263.
71. Griffin M, Ray W, Schaffner W Non-steroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988, 109:359-363.
72. Nuki G Pain control and the use of non-steroidal analgesic anti-inflammatory drugs. Br Med Bull 1990, 46:262-278.
73. Weinblatt M Nonsteroidal anti-inflammatory drug toxicity: increased risk in the elderly. Scand J Rheumatol Suppl 1991, 91:9-17.
74. Clark D, Ghose K Neuropsychiatric reactions to nonsteroidal anti-inflammatory drugs. The New Zealand experience. Drug Safety 1992, 7:460-465.
75. Fries J, Williams C, Bloch D The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991, 34:1353-1360.
76. Smalley W, Griffin M The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996, 25:373-396.
77. Morgan G, Poland M, DeLapp R Efficacy and safety of nabumetone vs. diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993, 95:19S-27S.
78. Fries J NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991, 18(Suppl 28):6-10.
79. Smalley W, Griffin M, Ray W Costs for treatment of upper gastrointestinal disease attributable to nonsteroidal anti-inflammatory drug (NSAID) use in the elderly Medicaid recipients. Gastroenterology 1993, 104:A194.
80. Singh G Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.
81. Roth S Non-steroidal anti-inflammatory drugs: Gastropathy, deaths and medical practice. Ann Intern Med 1988, 109:353-354.
82. Caruso I, Bianchi Porro G Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980, 1:75-78.
83. Scheiman J NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996, 25:279-296.
84. Gabriel S, Jaakkimainen L, Bombardier C Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
85. Laine L Helicobacter pylori, gastric ulcer, and agents noxious to the gastric mucosa. Gastroenterol Clin North Am 1993, 22:117-125.
86. Smale S, Tibble J, Sigthorsson G, Bjarnason I Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Practice Res Clin Gastroenterol 2001, 15:723-738.
87. Bjarnason I Experimental evidence of the benefit of misoprostol beyond the stomach in humans. J Rheumatol Suppl 1990, 20:38-41.
88. Tibble JA, Sigthorsson G, Foster R, Bjarnason I Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000, 35:802-807.
89. Sievert W, Stern A, Lambert J, Peacock T Low dose antacids and nonsteroidal anti-inflammatory drug-induced gastropathy in humans. J Clin Gastroenterol 1991, 13(Suppl 1):S145-S148.
90. Roth S, Bennett R, Mitchell C, et al. Cimetidine therapy in non-steroidal anti-inflammatory drug gastropathy. Arch Int Med 1987, 147:1799-1801.
91. Ehsanullah R, Page M, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. BMJ 1988, 297:1017-1021.
92. Rachmilewitz D The role of H2-receptor antagonists in the prevention of NSAID-induced gastrointestinal damage. Aliment Pharmacol Ther 1988, 2:65-73.
93. Robinson M, Mills R, Euler A Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 1991, 5:143-150.
94. Agrawal N, Roth S, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug induced gastric ulcer. Ann Intern Med 1991, 115:195-200.
95. Miglioli M, Porro G, Vaira D, et al. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Am J Gastroenterol 1996, 91:2367-2371.
96. Agrawal N, Dajani E Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs. J Assoc Acad Minor Phys 1992, 3:142-148.
97. Chan F, Hung L, Bing S, et al: Celecoxib vs diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med., 347 (26):2104-2110.
98. Murray M, Brater D Adverse effects of nonsteroidal drugs on renal function. Ann Intern Med 1990, 112:559-560.
99. Corwin H, Bonventre J Renal insufficiency associated with nonsteroidal anti-inflammatory agents. Am J Kidney Dis 1984, 4:147-152.
100. Dunn M, Simonson M, Davidson E, et al. Non-steroidal anti-inflammatory drugs and renal function. J Clin Pharmacol 1988, 28:524-529.
101. Carmichael J, Shankel S Renal effects of nonsteroidal anti-inflammatory drugs. Am J Med 1985, 78:992-1000.
102. Zambraski E The effects of nonsteroidal anti-inflammatory drugs on renal function: Experimental studies in animals. Sem Nephrol 1995, 15:205-213.
103. Sraer J, Siess W, Moulonguet-Doleris L, et al. In vitro prostaglandin synthesis by various rat renal preparations. Biochim Biophys Acta 1982, 15:45-52.
104. Palmer B, Henrich W Clinical acute renal failure with non-steroidal anti-inflammatory drugs. Sem Nephrol 1995, 15:214-227.
105. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990, 15:475-481.
106. Mizuiri S, Takano M, Hayashi I, et al. Effects of prostaglandins on renal function in uninephrectomized humans. Nephron 1993, 63:429-433.
107. Donker A, Arisz L, Brentjens J, et al. Effect of indomethacin on kidney function and plasma renin activity in man. Nephron 1976, 16:288-296.
108. Davis A, Day R, Begg B Interactions between non-steroidal anti-inflammatory drugs and anti-hypertensive diuretics. Aust NZ J Med 1986, 16:537-546.
109. Weiss Y, et al. Maintenance of blood pressure control in elderly hypertensives on ketoprofen. Scand J Rheumatol Suppl 1991, 91:37-44.
110. Pope J, Anderson J, Felson D A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477-484.
111. Mene P, Pugliese F, Patrono C The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Sem Nephrol 1995, 15:244-252.
112. Clabattoni G, Pugliese F, Cinotti G, Patrono C Renal effects of antiinflammatory drugs. Eur J Rheumatol 1980, 3:210-221.
113. Eriksson L, Bostrom H Deactivation of sulindac-sulphide by human renal microsomes. Pharm Toxicol 1988, 62:177-183.
114. Perazella M, Buller G Can ibuprofen cause acute renal failure in a normal individual?. Am J Kidney Dis 1991, 18:600-602.
115. Shibasaki T, et al. Clinical characterization of drug-induced allergic nephritis. Am J Nephrol 1991, 11:174-180.
116. Kleinknecht D Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal atni-inflammatory drugs. Sem Nephrol 1995, 15:228-235.
117. Brater D Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2 selective inhibition. Am J Med 1999, 107:65S-71S.
118. Schafer A Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995, 35:209-219.
119. Jaffe E, Weksler B Recovery of endothelial cell prostacyclin production after inhibition of low doses of aspirin. J Clin Invest 1979, 63:532-535.
120. Burns E, Lawrence C Bleeding time: a guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989, 113:1219-1224.
121. Lind S The bleeding time does not predict surgical bleeding. Blood 1991, 77:2547-2552.
122. McGurk M, Dinsdale R A comparison of template bleeding time with mucosal petechiometry as a measure of the platelet function defect induced by aspirin. Br J Oral Maxillofac Surg 1991, 29:173-175.
123. Kantor T Peripherally-acting analgesics. Analgesics: Neurochemical, Behavioral, and Clinical Perspectives 1984, 289-312. Raven Press, New York. M. Kuhar, G. Pasternak (Eds.).
124. McIntyre B, Philp R, Inwood J Effect of ibuprofen on platelet function in normal subjects and hemophilic patients. Clin Pharmacol Ther 1978, 24:616-621.
125. Weintraub M, Case K, Kroening B Effects of piroxicam on platelet aggregation. Clin Pharmacol Ther 1978, 23:134-135.
126. An H, Mikhail W, et al. Effects of hypotensive anesthesia, nonsteroidal antiinflammatory drugs, and polymethylmethacrylate on bleeding in total hip arthroplasty patients. J Arthroplasty 1991, 6:245-250.
127. Connelly C, Panush R Should nonsteroidal antiinflammatory drugs be stopped before elective surgery?. Arch Intern Med 1991, 151:1963-1966.
128. Lindgren U, Djupsjo H Diclofenac for pain after hip surgery. Acta Anaesthesiol Scand 1985, 56:28-31.
129. Bricker S, Savage M, Hanning C Perioperative blood loss and nonsteroidal antiinflammatory drugs: An investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol 1987, 4:429-434.
130. Shorr R, Ra W, Daugherty J, Griffin M Concurrent use of nonsteroidal antiinflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993, 153:1665-1670.
131. Greenberg H, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000, 40:1509-1515.
132. Leese P, Hubbard R, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol. 2000, 40:124-132.
133. Leese P, Talwalker S, Kent J, Recker D Valdecoxib does not impair platelet function. Am J Emerg Med 2002, 20:275-281.
134. Kromaann-Anderson H, Pedersen A Reported adverse reactions to and consumption of nonsteroidal anti-inflammatory drugs in Denmark over a 17-year period. Danish Med Bull 1988, 35:187-192.
135. Rabinovitz M, Van Thiel D Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992, 87:1696-1704.
136. Fry S, Seeff L Hepatotoxicity of analgesics and antiinflammatory agents. Gastroenterol Clin North Am 1995, 24:875-905.
137. Helfgott S, Sandberg-Cook J, Zakim D, Nestler J Diclofenac associated hepatotoxicity. JAMA 1990, 264:2660-2662.
138. Babany G, Bernau J, Danaw G, et al. Fulminating hepatitis in a woman taking glafenine and diclofenac. Gastroenterol Clin Biol 1985, 9:185.
139. Gay G Another side effect of NSAIDs. JAMA 1990, 264:2677-2678.
140. Gerstenfeld L, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. J Orthop Res 2003, 21:670-675.
141. Neal B Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty (Cochrane Review). The Cochrane Library, Issue 4 2001, Update Software, Oxford.
142. Perlman M, Thordarson D Ankle fusion in a high risk population: An assessment of nonunion risk factors. Foot Ankle Int 1999, 20:491-496.
143. Alho A Internally fixed femoral neck fractures. Early prediction of failures in 203 elderly patients with displaced fractures. Acta Orthop Scand 1999, 70:141-144.
144. Bhandari M Reamed versus nonreamed intramedullary nailing of lower extremity long bone fractures: A systematic overview and meta-analysis. J Orthop Trauma 2000, 14:2-9.
145. Karladani A The influence of fracture etiology and type of fracture healing: A review of 104 consecutive tibial shaft fractures. Arch Orthop Trauma Surg 2001, 121:325-328.
146. Giannoudis PV, et al. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000, 82:655-658.
147. Maxy R, Glassman S The effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion. Regional Anesthesia Pain Med 2001, 26:156-158.
148. Glassman S, Rose S, Dimar J, et al. The effect of postoperative nonsteroidal anti-inflammatory drug administraton on spinal fusion. Spine 1998, 23:834-838.
149. Gerstenfeld L, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. J Orthop Res 2003, 21:670-675.
150. Einhorn T Do inhibitors of cyclooxygenase-2 impair bone healing?. J Bone Mineral Res 2002, 17:977-979.
151. Jeffcoat M The effect of systemic flurbiprofen on bone supporting dental implants. JADA 1995, 126:305-311.
152. Brägger U Effect of the NSAID flurbiprofen on remodelling after periodontal surgery. J Periodontal Res 1997, 32:375-382.
153. Bichara J The effect of postsurgical naproxen and a bioabsorbable membrane on osseous healing in intrabony defects. J Periodontol 1999, 70:869-877.
154. Szczeklik A, Nizankowska E, Mastalerz L, Szabo Z Analgesics and asthma. Am J Therap 2002, 9:233-243.
155. Salvi S, Krishna T, Sampson A, Holgate S The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2000, 118:1470-1476.
156. Dahlen B, Szczeklik A, Murray J Celecoxib in patients with asthma and aspirin intolerance. N Engl J Med 2001, 344:142.
157. Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Experim Allergy 2001, 31:219-225.
158. Farrell G Liver disease produced by non-steroidal anti-inflammatory drugs. Drug-induced Liver Disease 1994, 371. Churchill-Livingstone, Edinburgh. G. Farrell (Ed.).
159. Carson J, Strom B, Morse M, et al. The relative gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs. Arch Int Med 1987, 147:1054-1059.
160. Roberts D, Gerber J, Barnes J, et al. Sulindac is not renal sparing in man. Clin Pharmacol Ther 1985, 38:258-265.
161. Quintero E, Gines P, Arroyo V, et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 1986, 42:298-303.
162. Stouten E, Armbruster S, Houmes R, et al. Comparison of ketorolac and morphine for postoperative pain after major surgery. Acta Anaesthesiol Scand 1992, 36:716-721.
163. Brown C, Mazzulla J, Mok M, et al. Comparison of repeat doses of intramuscular ketorolac tromethamine and morphine sulfate for analgesia after major surgery. Pharmacotherapy 1990, 10:45S-50S.
164. Bosek V, Smith D, Cox C Ketorolac or fentanyl to supplement local anesthesia?. J Clin Anesth 1992, 4:480-483.
165. Greer I Effects of ketorolac tomethamine on hemostasis. Pharmacotherapy 1990, 10:71S-76S.
166. Garcha I, Bostwick J Postoperative hematomas associated with Toradol [letter]. Plast Reconstr Surg 1991, 88:919-920.
167. Forbes J, et al. Evaluation of ketorolac, ibuprofen, acetaminophen, and an acetaminophencodeine combination in postoperative oral surgery pain. Pharmacotherapy 1990, 10:94S-105S.
168. Rhodes M Nonsteroidal antiinflammatory drugs for postthoracotomy pain. J Thorac Cardiovasc Surg 1992, 103:17-20.
169. Miller L Oxaprozin: A once-daily nonsteroidal anti-inflammatory drug. Clin Pharm 1992, 11:591-603.
170. Roberts L, Morrow J Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001, 714. McGraw-Hill, New York. ed 10. J. Hardman, L. Limbird (Eds.).
171. Med Lett 1972, 14:31.
172. Dahl S Nabumetone: A "nonacidic" nonsteroidal antiinflammatory drug. Ann Pharmacother 1993, 27:456-463.
173. Freed M, Audet P, Zariffa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 1994, 34:1098-1108.
174. FDA Advisory Committee Briefing Document, NDA 21-042, s007 VIOXX Gastrointestinal Safety. Source , 8 February 2001. http://www.fda.gov.
175. Ray W, Stein C, Daugherty J, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071-1073.
176. Solomon D, Schneeweiss S, Glynn R, et al: The relationship between selective COX-2 inhibitors and acute myocardial infarction. Abstract 1823 presented at the Am Coll of Rheumatology, September 2003.
177. Baigent C, Patrono C Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. Arthritis Rheumatism 2003, 48:12-20.
178. Forbes J, Beaver W, Jones K, et al. Evaluation of caffeine on ibuprofen analgesia in postoperative oral surgery pain. Clin Pharmacol Ther 1991, 49:674-684.
179. McQuay H, Angell K, Carroll D, et al. Ibuprofen compared with ibuprofen plus caffeine after third molar surgery. Pain 1996, 66:247-251.
180. Castaneda-Hernandez G, Castillo-Mendez M, Lopez-Munoz F, et al. Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced function impairment model in the rat. Can J Physiol Pharmacol 1994, 72:1127-1131.
181. Jin F, Chung F Multimodal analgesia for postoperative pain control. J Clin Anesthesia 2001, 13:524-539.
182. Paqueron X, Lumbroso A, Mergoni P, et al. Is morphine-induced sedation synonymous with analgesia during intravenous morphine titration?. Br J Anaesthesia 2002, 89:697-701.
183. Camu F, Vanlersberghe C Pharmacology of systemic analgesics. Best Practice Res Clin Anaesthesiol 2002, 16:475-488.
184. Alexander R, El-Moalem H, Gan T Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery. J Clin Anesthesia 2002, 14:187-192.
185. Mather L Do the pharmacodynamics of the nonsteroidal anti-inflammatory drugs suggest a role in the management of postoperative pain?. Drugs 1992, 44(Suppl 5):1-12.
186. Camu F, Beecher T, Recker D, Verburg K Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Therap 2002, 9:43-51.
187. Munro H, Walton S, Malviya S, et al. Low-dose ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents. Can J Anaesthesia 2002, 49:461-466.
188. Eisenberg E, Berkey C, Carr D, Mosteller F Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis. J Clin Oncol 1994, 12:2756-2765.
189. Barton S, Langeland F, Snabes M, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002, 97:306-314.
190. Steen M, Kehlet H, Jørgen Berg D A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: The role of timing of analgesia. Anesthesiology 2002, 96:725-741.
191. Stone A, Broderick J, Kaell A, et al. Does the peak-end phenomenon observed in laboratory pain studies apply to real-world pain in rheumatoid arthritics?. J Pain 2000, 1:212-217.
192. Reuben S, Bhopatkar S, Maciolek H, et al. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesthesia Analgesia 2002, 94:55-59.
193. Matheson A, Figgitt D Rofecoxib: A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001, 61:833-865.
194. Clemett D, Goa K Celecoxib: S review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000, 59:957-980.
195. Desjardins PJ, Shu VS, Recker DP, et al. A single preoperative dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 2002, 97:565-573.
196. Daniels SE, Desjardins PJ, Talewaker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. JADA 2002, 133:611-621.
197. Malan TP, Marsh G, Hakki SI, et al. Parecoxib sodium, a parenteral cyclooxygenasae 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003, 98:950-956.
198. Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cycloxygenase 2 inhibitor on pain management and recovery of function after knee replacement: A randomized controlled trial. JAMA 2003, 290:2411-2418.
199. Reuben SS, Connelly NR Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000, 91:1221-1225.
200. Barton SF, Langeland FF, Snabes MC, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002, 97:306-314.
201. Sinatra RS, Shen QJ, Halaszynski T, et al. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: The effects of an effort-dependent pain and pulmonary function. Anesth Analg 2003, 98:135-140.
202. Forslund C, Bylander B, Aspenberg P Indomethacin and celecoxib improve tendon healing in rats. Acta Orthop Scand 2003, 74:465-469.
203. Monck N NO-naproxen (AstraZeneca). Idrugs 2003, 6:593-599.